1. Gottesman, M. M.; Fojo, T.; Bates, S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002;2:48-58.
2. Ueda, K., ABC proteins protect the human body and maintain optimal health. Biosci. Biotechnol. Biochem. 2011;75:401-9.
3. Shukla, S.; Ohnuma, S.; Ambudkar, S. V., Improving cancer chemotherapy with modulators of ABC drug transporters. Curr. Drug Targets 2011;12:621-630.
4. Slater, L. M.; Sweet, P.; Stupecky, M., et al., Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 1986;77:1405-8.
5. Tsuruo, T.; Iida, H.; Tsukagoshi, S., et al., Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967-72.
6. Boesch, D.; Gaveriaux, C.; Jachez, B., et al., In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991;51:4226-33.
7. Germann, U. A.; Shlyakhter, D.; Mason, V. S., et al., Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 1997;8:125-40.
8. Dantzig, A. H.; Shepard, R. L.; Cao, J., et al., Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996;56:4171-9.
9. Roe, M.; Folkes, A.; Ashworth, P., et al., Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg. Med. Chem. Lett. 1999;9:595-600.
10. Allikmets, R.; Schriml, L. M.; Hutchinson, A., et al., A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998;58:5337-9.
11. Doyle, L. A.; Yang, W.; Abruzzo, L. V., et al., A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1998;95:15665-15670.
12. Miyake, K.; Mickley, L.; Litman, T., et al., Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 1999;59:8-13.
13. Aronica, E.; Gorter, J. A.; Redeker, S., et al., Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005;46:849-57.
14. Fetsch, P. A.; Abati, A.; Litman, T., et al., Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 2006;235:84-92.
15. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F., et al., Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues. Cancer Res. 2001;61:3458-3464.
16. Noguchi, K.; Katayama, K.; Sugimoto, Y., Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers. Med. 2014;7:53-64.
17. Burger, H.; van Tol, H.; Boersma, A. W., et al., Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2.
18. Elkind, N. B.; Szentpetery, Z.; Apati, A., et al., Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 2005;65:1770-7.
19. Maliepaard, M.; van Gastelen, M. A.; Tohgo, A., et al., Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res. 2001;7:935-41.
20. Robey, R. W.; Medina-Perez, W. Y.; Nishiyama, K., et al., Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 2001;7:145-52.
21. Rabindran, S. K.; He, H.; Singh, M., et al., Reversal of a Novel Multidrug Resistance Mechanism in Human Colon Carcinoma Cells by Fumitremorgin C. Cancer Res. 1998;58:5850-5858.
22. Nishiyama, M.; Kuga, T., Central Effects of the Neurotropic Mycotoxin Fumitremorgin A in the Rabbit (I) Effects on the Spinal Cord. The Japanese Journal of Pharmacology 1989;50:167-173.
23. Rabindran, S. K.; Ross, D. D.; Doyle, L. A., et al., Fumitremorgin C Reverses Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein. Cancer Res. 2000;60:47-50.
24. Weidner, L. D.; Zoghbi, S. S.; Lu, S., et al., The Inhibitor Ko143 Is Not Specific for ABCG2. The Journal of pharmacology and experimental therapeutics 2015;354:384-393.
25. Gupta, A.; Dai, Y.; Vethanayagam, R. R., et al., Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother. Pharmacol. 2006;58:374-383.
26. Chearwae, W.; Shukla, S.; Limtrakul, P., et al., Modulation of the function of the multidrug resistance–linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther. 2006;5:1995-2006.
27. Robey, R. W.; Steadman, K.; Polgar, O., et al., Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition. Cancer Res. 2004;64:1242-6.
28. de Bruin, M.; Miyake, K.; Litman, T., et al., Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. 1999;146:117-126.
29. Yanase, K.; Tsukahara, S.; Asada, S., et al., Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 2004;3:1119-25.
30. Houghton, P. J.; Germain, G. S.; Harwood, F. C., et al., Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004;64:2333-7.
31. Henrich, C. J.; Bokesch, H. R.; Dean, M., et al., A high-throughput cell-based assay for inhibitors of ABCG2 activity. J. Biomol. Screen. 2006;11:176-83.
32. Henrich, C. J.; Robey, R. W.; Bokesch, H. R., et al., New inhibitors of ABCG2 identified by high-throughput screening. Mol. Cancer Ther. 2007;6:3271-8.
33. Robey, R. W.; Honjo, Y.; van de Laar, A., et al., A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochimica et Biophysica Acta (BBA) - Biomembranes 2001;1512:171-182.
34. Candeil, L.; Gourdier, I.; Peyron, D., et al., ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int. J. Cancer 2004;109:848-54.
35. Gallus, J.; Juvale, K.; Wiese, M., Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochimica et Biophysica Acta (BBA) - Biomembranes 2014;1838:2929-2938.
36. Glavinas, H.; Kis, E.; Pál, Á., et al., ABCG2 (Breast Cancer Resistance Protein/Mitoxantrone Resistance-Associated Protein) ATPase Assay: A Useful Tool to Detect Drug-Transporter Interactions. Drug Metabolism and Disposition 2007;35:1533-1542.
37. Ambudkar, S. V., Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol. 1998;292:504-14.
38. Yamazaki, R.; Nishiyama, Y.; Furuta, T., et al., Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol. Cancer Ther. 2011;10:1252-63.
39. Allen, J. D.; van Loevezijn, A.; Lakhai, J. M., et al., Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C Mol. Cancer Ther. 2002;1:417-25.
40. Nakanishi, T.; Ross, D. D., Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin. J. Cancer 2012;31:73-99.
41. Aslanis, V.; Zhang, J.; Lomeli, B., et al., Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. Cancer Chemother. Pharmacol. 2018;82:847-855.
42. Huguet, J.; Lu, J.; Gaudette, F., et al., No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects. Eur. J. Clin. Pharmacol. 2016;72:925-931.
43. Guo, L. Q.; Yamazoe, Y., Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol. Sin. 2004;25:129-36.
44. Gupta, A. K.; Anderson, T. F., Psoralen photochemotherapy. J. Am. Acad. Dermatol. 1987;17:703-34.
論文の公開元へ
